It has been ten years since anti-vascular endothelial growth factor (anti-VEGF) drugs were officially listed. During these ten years, the effects of anti-VEGF drugs have been recognized by eye care professionals and, in turn, these drugs have propelled the development of ophthalmology and the related health care industry. This article reviews the development course of anti-VEGF drugs, and analyzes the impact of anti-VEGF drugs on clinical practice, ophthalmological academia and the business market.
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE[J]. Ophthalmology,2012,119(4):789-801.
[2]
Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study[J]. Ophthalmology,2009, 116(11): 2175-2181.
[3]
Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)[J]. Ophthalmology,2013,120(11):2292-2299.
[4]
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration[J]. N Engl J Med, 2006,355(14):1419-1431.
[5]
Thach AB, Yau L, Hoang C, et al. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials[J]. Ophthalmology,2014, 121(5):1059-1066.
[6]
Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med,1971,285(21):1182-1186.
[7]
Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells[J]. Biochem Biophys Res Commun,1989,161(2):851-858.
[8]
Breakthrough of the year. Areas to watch in 2007[J]. Science, 2006,314(5807):1854-1855.
[9]
Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study[J]. Diabetes Care,2010,33(11):2399-2405.
[10]
Bressler NM, Varma R, Suner IJ, et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE[J]. Ophthalmology,2014,121(12):2461-2472.
[11]
Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study[J]. Ophthalmology,2010,117(6):1102-1112.
[12]
Campochiaro PA, Bhisitkul RB, Shapiro H, et al. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion[J]. Ophthalmology,2013, 120(4):795-802.
[13]
Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration[J]. Ophthalmology,2012,119(12):2537-2548.
[14]
Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema[J]. Ophthalmology,2014,121(11):2247-2254.
[15]
Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study[J]. Ophthalmology,2014,121(9):1740-1747.
[16]
Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration[J]. N Engl J Med,2011,364(20):1897-1908.
[17]
Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration[J].Arch Ophthalmol,2011,129(6):709-717.
[18]
Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010[J]. Am J Ophthalmol,2012,153(2):209-213.
[19]
Skaat A, Chetrit A, Belkin M, et al. Time trends in the incidence and causes of blindness in Israel[J]. Am J Ophthalmol, 2012,153(2):214-221.
[20]
Hosseini H, Nejabat M. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents[J]. Med Hypotheses,2007,68(4):799-801.
[21]
Finger PT, Chin KJ. Refractory squamo us cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study[J]. Ophthal Plast Reconstr Surg,2012,28(2): 85-89.
[22]
Yeh S, Albini TA, Moshfeghi AA, et al. Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation[J]. Am J Ophthalmol,2012,154(3):429-435.
[23]
Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma[J].Curr Opin Ophthalmol,2010,21(2):112-117.
[24]
Houston SK, Shah NV, Decatur C, et al. Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment[J]. Clin Ophthalmol,2013,7:193-198.
[25]
Chiang A, Bianciotto C, Maguire JI, et al. Intravitreal bevacizumab for choroidal neovascularization associated with choroidal nevus[J]. Retina,2012,32(1):60-67.
[26]
Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia[J].Ophthalmology,2014,121(3): 682-692.
[27]
Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study[J]. Ophthalmology,2013,120(9):1944-1945.
[28]
Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR Study[J]. Ophthalmology,2015, 122(6):1220-1227.
[29]
Stone EM. A very effective treatment for neovascular macular degeneration[J]. N Engl J Med,2006,355(14):1493-1495.
[30]
Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial[J]. Lancet,2013,382(9900):1258-1267.
Ken Research. The US pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment[R]. Mar 01, 2012.
[35]
Decision Resources Group. The Age-Related Macular Degeneration Drug Market Will Grow to Nearly $9 Billion in 2023, Fueled in Part by the Anticipated Launch of the First Therapies for Geographic Atrophy[R]. Burlington,Oct 20,2014.